Cosmo Pharmaceuticals N.V (C43) — Capital Reinvestment Ratio
Cosmo Pharmaceuticals N.V (C43) has a Capital Reinvestment Ratio of 0.18x as of June 2022, meaning it reinvests 0% of its operating cash flow (€6.28 Million) in capital expenditures (€1.11 Million). Check Cosmo Pharmaceuticals N.V tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cosmo Pharmaceuticals N.V Capital Reinvestment Ratio (2016–2024)
This chart tracks Cosmo Pharmaceuticals N.V's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Cosmo Pharmaceuticals N.V.
Annual Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V from 2016 to 2024. See Cosmo Pharmaceuticals N.V free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €162.41 Million | €5.65 Million | ▼ -92.4% |
| 2023 | 0.46x | €33.62 Million | €15.31 Million | ▲ +107.0% |
| 2022 | 0.22x | €33.23 Million | €7.31 Million | ▼ -49.4% |
| 2021 | 0.44x | €12.61 Million | €5.49 Million | ▲ +37.1% |
| 2020 | 0.32x | €12.98 Million | €4.12 Million | ▼ -62.6% |
| 2016 | 0.85x | €21.69 Million | €18.43 Million | — |